FDA RDEP eligibility for REP-0003 in HoFH strengthens a rare disease pathway with implications beyond inherited cholesterol disorders.
For all the progress made in lowering cholesterol and reducing cardiovascular risk, medicine still has remarkably few options for removing the cellular damage that accumulates once atherosclerosis is established. That distinction lies at the heart of Repair Biotechnologies‘ approach; rather than modifying lipid levels alone, the company’s investigational therapy is designed to eliminate excess intracellular free cholesterol, a toxic driver of plaque formation that has proved difficult to target directly.
Homozygous familial hypercholesterolemia leaves little room for gradualism. LDL levels that would alarm a cardiologist in an adult are, in HoFH patients, present from birth – and the atherosclerotic damage accumulates accordingly. Into that high-need, well-defined space, the FDA has now granted Rare Disease Evidence Principles (RDEP) eligibility to REP-0003, Repair Biotechnologies’ investigational mRNA therapy – a designation that, alongside the company’s existing Orphan Drug Designation, offers a more tractable evidentiary pathway to clinical development [1].
Longevity.Technology: Repair Biotechnologies’ FDA eligibility for REP-0003 under the RDEP pathway is, on the surface, a rare disease regulatory story – but longevity biotech rarely stays politely on the surface. HoFH offers a tightly-defined, high-need indication in which the biology is extreme enough to make clinical development more tractable; however, the underlying target – the pathological accumulation of intracellular free cholesterol – gestures toward a much larger question in cardiovascular aging. For decades, the therapeutic orthodoxy has been to manage risk, slow progression and keep the plumbing from getting worse, which is sensible enough, if not exactly thrilling; Repair’s thesis is more radical, namely that some of the cellular damage driving atherosclerosis may be removable, not merely negotiable. If cardiovascular disease becomes one of the first arenas in which damage-repair geroscience can be tested against imaging, function and ultimately outcomes, then HoFH may prove less a niche endpoint than a narrow doorway into a much broader age-related disease landscape. To explore where HoFH fits within Repair’s longer-term ambitions – and whether cardiovascular disease could become one of the first proving grounds for genuine damage-repair therapies – we spoke with founder and CEO Reason.
A rare disease with broader ambitions
Although REP-0003 is entering development through HoFH, Reason makes it clear that the rare disease indication is as much a practical starting point as a scientific destination. The combination of a well-defined patient population, established regulatory incentives and pronounced disease biology makes HoFH an attractive first clinical target, even if the mechanism itself has much wider relevance.
“HoFH is an easier first target than most other indications for a number of reasons, both the usual regulatory ones and some of the biochemistry we discovered along the way,” he says. “Since we have Orphan Drug Designation for HoFH we can’t delve too deeply into a discussion of atherosclerosis more generally, but it seems clear from the existing literature on excess intracellular free cholesterol in the liver, retina, brain and other tissues, that targeting it is an important novel approach that should be tried for many classes of age-related disease.”
The implication is that intracellular free cholesterol represents a shared pathological mechanism extending well beyond inherited lipid disorders. While REP-0003 currently focuses on hepatic delivery, Reason says different tissues are likely to require different therapeutic approaches as the platform evolves.
“There will be many different modes and distributions of delivery outside the liver that would be suited to those other conditions,” he says. “For example we experimented with AAV-mediated gene therapy and generating macrophage lines for cell therapy earlier in the company’s history. That latter approach would probably be replaced nowadays with some form of macrophage-targeted gene therapy, as the first of these are now emerging.”
Beyond managing cardiovascular disease
The broader ambition naturally raises a more provocative question – at what point does repairing diseased tissue become something meaningfully different from simply managing cardiovascular risk?
For Reason, one of the earliest indicators would not necessarily be an imaging result, but a functional one.
“Unlike all other atherosclerotic cardiovascular disease (ASCVD) therapies, either approved or in development, REP-0003/REP-0004 produce a clear, rapid functional benefit in preclinical studies, specifically an increase in exercise tolerance,” he says. “It is that functional benefit and the continuation of that benefit after treatment that will be the first clear sign that a patient has been in some way repaired, if you will.”
Plaque regression itself remains an important endpoint, he adds, noting that decades of cardiovascular research have linked reductions in plaque burden with improved long-term outcomes. Yet the field has never had a therapy capable of producing large reductions in plaque volume before being tested in randomized controlled trials, leaving regulators understandably cautious about interpreting such changes as evidence of rejuvenation.
“This is, in microcosm, the challenge faced by nearly all putative rejuvenation therapies,” he says. “You can demonstrate changes in many markers in the short term, but it remains the case that the only real way to determine whether rejuvenation occurred is to wait and see what happens to mortality risk over time.”
That challenge extends beyond cardiovascular disease, touching almost every area of geroscience.
“We can’t yet define and measure biological age in a way that everyone agrees upon and can be assessed immediately following treatment,” Reason continues. “You can satisfy one of those two constraints: everyone agrees on the rising mortality risk due to intrinsic causes definition of aging, which requires at minimum five to 10 years of followup, while there is no consensus on any of the possible short-term measures, such as aging clocks.”
Repair rather than risk reduction
Asked where cholesterol-clearance therapies fit within the broader longevity landscape, Reason is unequivocal that intermittent repair therapies will ultimately prove more transformative than lifelong risk modification.
“With regard to ongoing therapies versus intermittent repair therapies, well, the future has to be repair,” he says.
He contrasts established LDL-lowering therapies, which can reduce cardiovascular risk incrementally over many years, with approaches designed to remove accumulated damage directly.
“In preclinical models of ASCVD the results are night and day: small, slow gains from the LDL-lowering approaches, and very large gains from the repair approach.”
Reason sees the same distinction emerging across aging biology more broadly, drawing a parallel with senescence.
“Do you want a therapy that somewhat reduces the increase in your burden of senescent cells over decades of time? There are plenty of those in the calorie restriction and exercise mimetic portfolio. Or do you want to take senolytic treatments every so often and dramatically reduce the burden immediately whenever you do?”
For him, the answer is straightforward.
“The repair approach is clearly superior from a logistics perspective, and so far in the data obtained from preclinical animal studies.”
From hypothesis to evidence
The clinical evidence will arrive slowly, as it always does. But the proposition being tested here is not really about HoFH, or even about plaques. Repair Biotechnologies is making a bet that some of what we call cardiovascular disease is, at its root, damage – and that damage, unlike risk, can actually be undone. Whether that bet pays out is a question for the trials. That it is finally being asked is something in itself.
